Power Law company profile

Blueprint Medicines

Biotech & Life Sciences · Cambridge, United States · Founded 2011 · IPO 2015 Unicorn

← All companies

A public taster of the full Dealroom platform — request a demo to explore live financials, founders, funding history, and market intelligence.

Valuation

$8.25B

Market cap · 2026

Revenue

$509M

Latest reported FY

Investors

7 investors on Blueprint Medicines's cap table

Sourced from Dealroom's funding history. Tap any card for that investor's profile.

Series A 3 investors entered at this stage

Third Rock Ventures

F-Prime

Eight Roads Ventures

Series B+ 4 investors entered at this stage

RA Capital Management

Nextech Invest

Casdin Capital

PFM Health Sciences

Global footprint

Where Blueprint Medicines has talent and traffic

AI talent share

0.7% of workforce is AI talent
(5 of 741 staff)

Core AI20.27%

Other AI30.4%

Non-AI workforce73699.33%

Web traffic by country

21K monthly visits
across markets

🇺🇸 United States63.8%

🇮🇳 India15.7%

🇨🇦 Canada5.7%

🇬🇧 United Kingdom3.8%

🇫🇷 France3.8%

Top 5 markets shown

Patent intelligence

$87M patent portfolio · 95 active families

Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with quality scores compared against same-sector peers.

Estimated portfolio value

$87M

1.1% of market cap · comparable to top peer Constellation Pharmaceuticals ($116M)

95 active patent families

Where Blueprint Medicines innovates Pharmaceutical medicinePyrimidineTautomerCombinatorial chemistryPharmaceutical Substances

Below peer median on Legal, Market

Quality vs same-sector peers

Blueprint Medicines on the five Patsnap quality dimensions

Blueprint Medicines in orange. Same-sector peers are the top filers by total patent value. All scores 0–100; higher is stronger.

Compare against

Patent quality scores (0–100)

Source: Dealroom Patent Intelligence · Patsnap

Tech-focus vs peers

Where Blueprint Medicines concentrates inside the peer cluster

Axes are the most-shared Patsnap topics across Blueprint Medicines and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).

Compare against

Top-topic prominence (rank inverted, 0–100)

Source: Dealroom Patent Intelligence · Patsnap top-10 topics per company

This is teaser data. The full per-sub-category breakdown, individual patent records, and quality-score history are on the Dealroom platform — request a demo to access.

See Blueprint Medicines on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Open in Dealroom Book a demo